Moderna stock surged following positive cancer-vaccine data, burning short sellers and spilling over into the semi sector.

REGN's Pasatru wins FDA approval for FOP, cutting new HO lesions by 90% or more and reducing clinician-assessed flare-ups.

Pasatru’s approval sets up a market battle in a rare indication where the only available treatment has generated disappointing sales.

In August 2026, Regeneron Pharmaceuticals announced that the US FDA approved Pasatru (garetosmab-grts) to reduce new heterotopic ossification lesions and flare-ups in adults with fibrodysplasia ossificans progressiva, based on positive Phase 3 OPTIMA trial results. This approval adds a rare-disease monoclonal antibody to Regeneron’s portfolio, reinforcing the company’s focus on specialized, high-complexity immunology therapies. We’ll now examine how Pasatru’s FOP approval, as an ultra-rare...

Regeneron Pharmaceuticals stock has delivered a 43.0% return over the past year, yet the broader valuation checks point to a more mixed picture rather than a clear bargain or obvious overpricing. With recent partnership activity and pipeline progress in the spotlight, investors are weighing how much of that is already reflected in the current US$840.84 share price. The 43.0% one year return signals that the market has already repriced Regeneron Pharmaceuticals positively. The key issue for...

Franklin Biotechnology Discovery has a much higher 13% five-year annualized return than a biotech index ETF’s 5.3%

GlobalData highlighted EyePoint’s Duravyu as a notable drug set to enter the wet AMD market by 2034.

EyePoint's Duravyu misses the phase III wet AMD study's primary goal, sending shares down 67%, but shows lower treatment burden and durable disease control.

Duravyu, EyePoint’s candidate for wet age-related macular degeneration, misses the mark, but muddled trial data may be to blame.

They are fairly risky, but their potential upside is massive.

They are way more than just GLP-1 stocks.

Two prominent biopharmaceutical names, Biohaven Ltd. (NYSE:BHVN) and Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), are deepening their relationship across oncology. On July 20, Biohaven announced a clinical supply agreement with Regeneron to evaluate the combination of BHV-1530 and Regeneron’s cemiplimab (Libtayo) in patients with solid tumors. BHV-1530’s novel topoisomerase I (TopoIx) payload generates immunogenic cell death and […]

BMS reveals plans for a new manufacturing hub in Houston, and Regeneron invests in startup developing a Dupixent competitor.

Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.

Regeneron's Eylea HD and Dupixent strength are fueling growth, while oncology gains and pipeline progress support its outlook.

Dividend, earnings and buybacks in focus Regeneron Pharmaceuticals (REGN) has given investors several fresh data points to consider after confirming a quarterly dividend, releasing second quarter and half year 2026 results, and updating on recent share repurchases. See our latest analysis for Regeneron Pharmaceuticals. Alongside the latest dividend and earnings update, Regeneron Pharmaceuticals’ recent share price return of 18.33% over 30 days and 9.72% over 90 days suggests momentum has...

Intellia's Q2 loss matches estimates, but revenues fall 46.2% as lower Regeneron collaboration revenues weigh on results.

CytomX Therapeutics (NASDAQ:CTMX) said its second-quarter focus remained on advancing Varseta-M, an EpCAM-targeting antibody-drug conjugate being developed for metastatic colorectal cancer, while expanding the program into combination regimens and additional gastrointestinal cancers. Chief Executiv

Intellia reports positive Phase III data for LONVOSI, resumes NEXI trials with new HLA safety insights, and maintains cash runway into 2028.

Regeneron (REGN) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

RARE beats Q2 earnings estimates as revenues surge year over year to a record quarterly high, driven by higher product sales across its portfolio.

REGN vs. INCY: Which Stock Is the Better Value Option?

Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.

The biotech's shares have stumbled after a guidance change, and investors are weighing whether this is the moment to step in or step aside.

AbbVie shares took a hit on Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate of analysts polled by FactSet. Adjusted earnings came in at $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.

AbbVie lowered its full-year adjusted earnings outlook to account for its acquisition of Apogee Therapeutics, as the company logged higher profit and revenue in the recent quarter.

Find insight on Sanofi, Haleon, Cochlear and more in the latest Market Talks covering the health care sector.

Sanofi wants to broaden the company’s productive partnership with Regeneron, its CEOs said. Elsewhere, Bristol Myers delayed two anticipated study readouts and a Shionogi-backed startup went public.

Moby summary of Regeneron Pharmaceuticals, Inc.'s Q2 2026 earnings call

Revenue surged 17% as Dupixent and EYLEA HD posted record sales.

Regeneron Pharmaceuticals stock has delivered a solid 36.1% return over the past year, yet the broader valuation checks point to a mixed picture rather than a clear bargain or clear overvaluation. Regeneron Pharmaceuticals has gained 36.1% over the last 12 months, which puts more attention on whether recent optimism is already reflected in the share price. On the one hand, progress in areas such as investigational therapies for food allergy can support expectations for future cash flows. On...

Total revenue surged 17% to $4.3 billion, fueled by a 38% jump in Dupixent sales and a 52% rise in EYLEA HD, as the company navigates competitive pressures and advances a deep pipeline.

Healthcare stocks declined late Thursday afternoon, with the NYSE Healthcare Index shedding 1.5% and

Regeneron Pharmaceuticals (NASDAQ:REGN) reported second-quarter revenue growth of 17% from a year earlier to $4.3 billion, supported by continued strength in Dupixent, EYLEA HD and Libtayo. Non-GAAP diluted earnings per share rose 11% to $14.29, while non-GAAP net income reached $1.5 billion. Chief

REGN's Q2 earnings and revenues beat estimates as robust Eylea HD demand and higher Dupixent profits offset declining Eylea sales.

Regeneron Pharmaceuticals reported past second-quarter 2026 results with revenue rising to US$4,290.7 million from US$3,675.6 million a year earlier, while net income slipped to US$1,296.9 million and diluted EPS from continuing operations softened to US$12.23. Alongside these mixed earnings, Regeneron recently entered a collaboration with Telix Pharmaceuticals to co-develop next-generation radiopharmaceutical oncology therapies, potentially broadening its precision-medicine footprint beyond...

While the top- and bottom-line numbers for Regeneron (REGN) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) reported stronger-than-expected second-quarter results, comfortably surpassing Wall Street forecasts for both earnings and revenue.

Regeneron (REGN) delivered earnings and revenue surprises of +42.90% and +11.74%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

July 30 () - Regeneron on Thursday beat Wall Street estimates for second-quarter revenue and profit, helped ‌by strong demand for its eczema drug Dupixent ‌and a high-dose version of its eye drug Eylea. Shares rose nearly ​5% before the bell.

Find insight on Sanofi, GE HealthCare Technologies and more in the latest Market Talks covering the health care sector.

Biotech company Regeneron (NASDAQ:REGN) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.

Regeneron tapped the Aussie biotech to enter the radiopharma market with a multi-pronged agreement.

Today Earnings (a.m.): Mastercard, Hershey, KKR, Yum Brands, Cigna, Regeneron, Valero Energy, Norwegian Cruise Line, Hyatt Hotels, Bristol-Myers Squibb, Altria, International Paper, SiriusXM, Blue Owl Capital Earnings (p.

The company now expects 2026 sales to grow by around 10% excluding currency changes, with business earnings per share rising slightly faster than sales.

Biotech company Regeneron (NASDAQ:REGN) will be reporting results this Thursday before the bell. Here’s what you need to know.

FDA calendars are stacking up fast, obesity Phase 3 data is closing in, and three biotech names spanning the risk spectrum are quietly positioning for a pivotal back half of 2026.

Today Federal Reserve meeting: Fed Chairman Kevin Warsh will hold a press conference at 2:30 p.m. ET, following the FOMC interest-rate decision at 2 p.m. Earnings (a.m): Procter & Gamble, Humana, L3Harris, Biogen, General Dynamics, Teva Pharmaceuticals, Airbus Earnings (p.

Regeneron's Q2 results could hinge on Dupixent profits and strong Eylea HD, Libtayo sales as investors watch earnings, buybacks and pipeline updates.

Today Earnings (a.m.): Coca-Cola, UPS, Boeing, Sherwin-Williams, Hilton, Centene, PayPal, S&P Global Earnings (p.m.): Visa, Ford Motor, Mondelez International, Waste Management, PPG Industries, Bloom Energy, Avis Budget, Seagate Technology Economic data: Consumer confidence index, Johnson Redbook retail sales index, U.